![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Transparency
Declaration of funding
The original manuscript was supported by Merck & Co. Inc., Kenilworth, NJ, USA.
Declaration of financial/other relationships
From the original manuscript, it was declared that Y.H. has received research grants, consultant & speaker honoraria from Amarin, Amgen, AZ, BMS, BI, BI-Lilly, Eisai, Intarcia, Janssen, Lexicon, Lilly, Merck Pfizer, Novo Nordisk, Regeneron, and Sanofi. B.L., I.G., C.I., E.A.O’N., Z.W., S.S., K.D.K., S.S.E. and E.L. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, who may own stock and/or hold stock options in the Company. CMRO peer reviewers on the original manuscript had no relevant financial or other relationships to disclose.
Acknowledgements
The original manuscript had editorial assistance provided by Jennifer Rotonda PhD and Michele McColgan BA of Merck & Co. Inc., Kenilworth, NJ. Trial registration numbers: Clinical Trials.gov: NCT01682759, EudraCT Number: 2012-002309-23.
Note
Notes
1 MARIZEV® is omarigliptin (Merck & Co., Inc., Kenilworth, NJ, USA; MSD outside of USA and Canada), a once-weekly DPP-4 inhibitor for type 2 diabetes, approved in Japan.